We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals
VRCA

39 hedge funds and large institutions have $25.3M invested in Verrica Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

4.68% less ownership

Funds ownership: 32.5% → 27.81% (-4.7%)

22% less funds holding

Funds holding: 50 → 39 (-11)

41% less capital invested

Capital invested by funds: $43.2M → $25.3M (-$17.9M)

63% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 16

Holders
39
Holders Change
-11
Holders Change %
-22%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
7
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Cannell Capital
Wyoming
+$4.39M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$456K
3
Marshall Wace
Marshall Wace
United Kingdom
+$354K
4
Squarepoint
Squarepoint
New York
+$269K
5
BlackRock
BlackRock
New York
+$210K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$3.85M
2
KCM
Kalehua Capital Management
Texas
-$1.96M
3
SCM
Stonepine Capital Management
Oregon
-$1.63M
4
Two Sigma Investments
Two Sigma Investments
New York
-$433K
5
Jane Street
Jane Street
New York
-$336K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAL
26
Capital Analysts LLC
Pennsylvania
$8K – – –
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$5K +$3.52K +549 +132%
VGA
28
Vanguard Global Advisers
Pennsylvania
$4.56K +$5.52K +862 New
TRCT
29
Tower Research Capital (TRC)
New York
$4.53K -$15.9K -2,486 -74%
SL
30
Salomon & Ludwin
Virginia
$1.59K – – –
NECFA
31
New England Capital Financial Advisors
Connecticut
$1.06K – – –
IAIM
32
International Assets Investment Management
Florida
$961 – – –
FFO
33
Fortitude Family Office
Arizona
$672 -$3.08K -481 -79%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$582 – – –
PNC Financial Services Group
35
PNC Financial Services Group
Pennsylvania
$540 – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$224 – – –
Optiver Holding
37
Optiver Holding
Netherlands
$164 – – –
Jones Financial Companies
38
Jones Financial Companies
Missouri
$114 +$166 +26 New
MCM
39
MAI Capital Management
Ohio
$11 – – –
KCM
40
Kalehua Capital Management
Texas
– -$1.96M -235,779 Closed
Two Sigma Advisers
41
Two Sigma Advisers
New York
– -$369K -44,430 Closed
SA
42
Sovran Advisors
California
– -$249K -32,658 Closed
Millennium Management
43
Millennium Management
New York
– -$192K -23,123 Closed
OAC
44
OMERS Administration Corp
Ontario, Canada
– -$188K -22,600 Closed
Goldman Sachs
45
Goldman Sachs
New York
– -$155K -18,621 Closed
HF
46
HRT Financial
New York
– -$144K -17,356 Closed
Walleye Capital
47
Walleye Capital
New York
– -$127K -15,240 Closed
XT
48
XTX Topco
Cayman Islands
– -$122K -14,662 Closed
BCM
49
Bridgeway Capital Management
Texas
– -$99.7K -12,000 Closed
QC
50
Quadrature Capital
United Kingdom
– -$99.3K -11,954 Closed
1
2
3

VRCA Hedge Fund Activity: Q1 2026 in Review

39 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2026, worth a combined $25.3M — down 41% from $43.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of VRCA and 6 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 10 added.

The largest buyer was Cannell Capital, opening a new position worth an estimated $4.39M. The largest seller was Armistice Capital, cutting an estimated $3.85M.

  • 39 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2026, down from 50 in Q4 2025.
  • Funds reported $25.3M of Verrica Pharmaceuticals stock for Q1 2026, down 41% quarter-over-quarter.
  • 6 funds opened new Verrica Pharmaceuticals positions in Q1 2026 and 16 closed out, a net change of -10 holders.
  • The largest Verrica Pharmaceuticals buyer in Q1 2026 was Cannell Capital, an estimated $4.39M added.
  • The largest Verrica Pharmaceuticals seller in Q1 2026 was Armistice Capital, an estimated $3.85M sold.

Based on aggregated 13F filings for Q1 2026.